Par Drugs & Chemical Intrinsic Value
PAR Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹173.80 | ₹139.04 - ₹208.56 | +96.1% | EPS: ₹7.90, Sector P/E: 22x |
| Book Value Method | asset | ₹165.00 | ₹148.50 - ₹181.50 | +86.2% | Book Value/Share: ₹82.50, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹170.00 | ₹153.00 - ₹187.00 | +91.8% | Revenue/Share: ₹85.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹138.62 | ₹124.76 - ₹152.48 | +56.4% | EBITDA: ₹17.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹136.16 | ₹108.93 - ₹163.39 | +53.6% | CF Growth: 7.5%, Discount: 15% |
| PEG Ratio Method | growth | ₹26.59 | ₹23.93 - ₹29.25 | -70.0% | EPS Growth: 1.3%, Fair P/E: 1.1x |
| Growth Adjusted P/E | growth | ₹123.23 | ₹110.91 - ₹135.55 | +39.1% | Revenue Growth: 8.0%, Adj P/E: 15.6x |
| ROE Based Valuation | profitability | ₹100.00 | ₹90.00 - ₹110.00 | +12.8% | ROE: 10.1%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹121.10 | ₹108.99 - ₹133.21 | +36.7% | EPS: ₹7.90, BVPS: ₹82.50 |
Want to compare with current market value? Check PAR share price latest .
Valuation Comparison Chart
PAR Intrinsic Value Analysis
What is the intrinsic value of PAR?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Par Drugs & Chemical (PAR) is ₹136.16 (median value). With the current market price of ₹88.62, this represents a +53.6% variance from our estimated fair value.
The valuation range spans from ₹26.59 to ₹173.80, indicating ₹26.59 - ₹173.80.
Is PAR undervalued or overvalued?
Based on our multi-method analysis, Par Drugs & Chemical (PAR) appears to be trading below calculated value by approximately 53.6%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 13.75 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.20 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 10.1% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 13.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.86x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Par Drugs & Chemical
Additional stock information and data for PAR
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹16 Cr | ₹4 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹20 Cr | ₹17 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹13 Cr | ₹10 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹8 Cr | ₹7 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹12 Cr | ₹12 Cr | Positive Free Cash Flow | 8/10 |